Psychopharmacology and Psychological Therapies

78 questions

Question 1Question →

A 2727-year-old man with a history of schizophrenia is brought to the emergency department by his family because he has been standing completely still in the corner of his room for the past 1212 hours. He does not respond to questions, maintains his arm in a raised position when the physician moves it there, and has not eaten or drank anything all day. His current medications include haloperidol and benztropine. Vital signs are temperature 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure 120/80 mm Hg120/80\text{ mm Hg}, pulse 82/min82/\text{min}, and respirations 14/min14/\text{min}. Arrange the following management steps in the most appropriate chronological order for this patient's current condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing catatonia is to first discontinue the offending antipsychotic, perform a lorazepam challenge, initiate scheduled benzodiazepines, and reserve ECT for refractory cases.
The patient is presenting with catatonia, characterized by immobility, mutism, waxy flexibility (maintaining a posture set by the examiner), and refusal to eat or drink. The management of catatonia follows a specific algorithm. The first step is to discontinue any potentially exacerbating medications, particularly dopamine antagonists (antipsychotics) like haloperidol, which can worsen the condition or trigger neuroleptic malignant syndrome. Once the offending agent is removed, the initial therapeutic and diagnostic step is the lorazepam challenge test (11-2 mg2\text{ mg} IV), which usually results in marked, rapid, but temporary improvement. Upon a positive challenge, the patient is transitioned to scheduled, standing doses of lorazepam to maintain remission. Electroconvulsive therapy (ECT) is considered the definitive treatment but is generally reserved for patients who fail to respond to a full trial of high-dose benzodiazepines, or for those presenting with malignant catatonia (catatonia accompanied by autonomic instability, fever, and rigidity).

Step-by-Step Solution

1
Identify the clinical syndrome.
The patient's mutism, immobility, waxy flexibility, and negativism are diagnostic of catatonia.
Accurate diagnosis is required to guide the specific algorithm for psychiatric intervention.
2
Determine the first step in management.
Discontinue haloperidol.
Dopamine-blocking agents (like haloperidol) can exacerbate catatonia and increase the risk of progression to neuroleptic malignant syndrome (NMS). They must be stopped immediately.
3
Select the initial pharmacological intervention.
Administer an intravenous lorazepam challenge.
Lorazepam 11 to 2 mg2\text{ mg} IV is used to confirm the diagnosis and typically provides rapid, temporary relief of catatonic symptoms.
4
Determine the maintenance strategy.
Initiate scheduled, continuous benzodiazepine therapy.
Because the lorazepam challenge only provides temporary relief, scheduled high-dose benzodiazepines are required to sustain improvement.
5
Identify the definitive treatment for refractory cases.
Prepare the patient for electroconvulsive therapy (ECT).
If the patient does not respond to benzodiazepines within several days, or if the catatonia becomes malignant (with fever and autonomic instability), ECT is the treatment of choice.

Key Concept

Algorithm for the Management of Catatonia
Question 2Question →

A patient with a recent history of ischemic heart disease is evaluated at an outpatient psychiatry practice. The 5858-year-old male suffered a myocardial infarction 33 months prior, for which he takes aspirin, ticagrelor, rosuvastatin, and metoprolol. He now describes a 66-week history of unremitting dysphoria, anhedonia, insomnia, and feelings of worthlessness, without any thoughts of self-harm. His physical examination and vital signs are unremarkable at this visit. A diagnosis of major depressive disorder is established, and pharmacotherapy is initiated. Eight days following this appointment, the patient arrives at the urgent care clinic complaining of severe dizziness and near-fainting episodes. Triage vital signs demonstrate a pulse of 40/min40\text{/min} and a blood pressure of 88/54 mm Hg88/54\text{ mm Hg}. A 1212-lead electrocardiogram confirms pronounced sinus bradycardia. Which of the following psychiatric medications is most likely responsible for precipitating this patient's acute presentation?

Show answer & explanation

Answer: Paroxetine

Answer

Paroxetine
The correct answer is the medication that acts as a potent CYP2D6 inhibitor. The patient's presentation of new-onset severe bradycardia and hypotension shortly after starting psychiatric therapy strongly suggests metoprolol toxicity. Metoprolol is extensively metabolized in the liver by the cytochrome P450 2D6 (CYP2D6) enzyme. Paroxetine (along with fluoxetine) is a potent inhibitor of CYP2D6. Co-administration of paroxetine blocks the clearance of metoprolol, leading to elevated beta-blocker concentrations and resulting in symptomatic bradycardia and cardiogenic presyncope.

Step-by-Step Solution

1
Identify the primary acute clinical syndrome.
The patient presents with severe sinus bradycardia and hypotension 8 days after starting a new medication.
This establishes that the patient is suffering from an acute adverse drug effect.
2
Analyze the patient's existing medication regimen for potential interactions.
The patient is taking metoprolol, a beta-blocker known to cause bradycardia and hypotension when serum levels are excessively high.
This links the acute symptoms to a potential toxicity of an existing medication rather than a direct effect of a new one.
3
Determine the metabolic pathway of metoprolol and evaluate the new medication choices.
Metoprolol is metabolized by CYP2D6. Among the choices, paroxetine is a potent CYP2D6 inhibitor, which would lead to decreased metoprolol clearance and subsequent toxicity.
Identifying the pharmacokinetic interaction correctly isolates the most likely causative agent.

Key Concept

Pharmacokinetic drug-drug interactions: Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) can severely decrease the metabolism of beta-blockers like metoprolol, precipitating dangerous bradycardia and hypotension.
Question 3Question →

A 31-year-old woman with severe, treatment-resistant atypical depression has failed multiple antidepressant trials. She is currently taking fluoxetine 60 mg daily but remains profoundly symptomatic. Her psychiatrist decides to transition her to phenelzine.

Arrange the following clinical steps in the correct chronological sequence to safely and effectively execute this medication transition and its long-term management.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with discontinuing fluoxetine, followed by a mandatory 5-week washout period. After the washout, phenelzine is initiated alongside a tyramine-restricted diet, followed by dose titration with orthostatic blood pressure monitoring. Finally, if phenelzine fails, a 2-week washout is required before starting a new serotonergic agent.
The correct sequence respects the unique pharmacokinetics of fluoxetine and the irreversible nature of MAOIs. Fluoxetine must be stopped, followed by a 5-week washout (due to norfluoxetine's long half-life). Phenelzine is then started alongside a low-tyramine diet to prevent hypertensive crisis. During titration, monitoring for orthostatic hypotension (the most common side effect) is critical. Finally, if phenelzine is stopped, a 14-day washout is required before starting a new serotonergic drug to allow for the regeneration of the MAO enzyme.

Step-by-Step Solution

1
Identify the medications involved in the transition.
The transition is from fluoxetine (an SSRI) to phenelzine (an MAOI).
Understanding the specific drugs dictates the pharmacokinetic rules required to prevent fatal drug interactions like Serotonin Syndrome.
2
Determine the required washout period for discontinuing fluoxetine.
A 5-week washout period is identified as mandatory.
Fluoxetine has a unique pharmacokinetic profile with a very long-acting metabolite (norfluoxetine), necessitating 5 weeks rather than the standard 2 weeks required for other antidepressants.
3
Establish the protocol for initiating the MAOI.
Phenelzine is started concurrently with a tyramine-restricted diet, followed by titration and blood pressure monitoring.
MAOIs inhibit the breakdown of tyramine, which can cause a hypertensive crisis if ingested. Furthermore, orthostatic hypotension is the most common dose-dependent side effect.
4
Establish the protocol for discontinuing the MAOI if it fails.
A 14-day (2-week) washout is required after stopping phenelzine.
Because phenelzine irreversibly inhibits MAO, it takes approximately 14 days for the body to synthesize a new supply of the enzyme before a serotonergic agent can be safely reintroduced.

Key Concept

Pharmacological transition protocols and washout periods between SSRIs and MAOIs.
Question 4Question →

Match each psychotropic medication with its most characteristic adverse effect, specific monitoring requirement, or clinical contraindication.

Click a left item, then click its matching right item

Items

Lamotrigine
Bupropion
Lithium
Clozapine

Matches

Show answer & explanation

Answer

Lamotrigine matches with severe cutaneous adverse reactions; Bupropion with contraindication in bulimia nervosa; Lithium with impaired renal concentrating ability; and Clozapine with absolute neutrophil count monitoring.
Each listed psychotropic medication has a classic and highly tested adverse effect profile. Lamotrigine requires very slow titration to avoid Stevens-Johnson syndrome. Bupropion lowers the seizure threshold and is specifically contraindicated in patients with eating disorders. Lithium frequently causes nephrogenic diabetes insipidus, presenting with polyuria and polydipsia. Clozapine requires strict ANC monitoring due to the known risk of potentially fatal agranulocytosis.

Step-by-Step Solution

1
Analyze Lamotrigine's primary adverse effect profile.
Identify that it requires slow titration to prevent life-threatening rashes like Stevens-Johnson syndrome.
This is a key clinical safety consideration when initiating Lamotrigine for bipolar disorder.
2
Recall the major contraindications for Bupropion.
Identify that it is contraindicated in bulimia nervosa and anorexia nervosa.
Electrolyte disturbances commonly seen in eating disorders compound Bupropion's known dose-dependent lowering of the seizure threshold.
3
Identify the primary renal toxicity associated with Lithium.
Match Lithium with polyuria, polydipsia, and nephrogenic diabetes insipidus.
Lithium antagonizes antidiuretic hormone action in the kidney, leading to an inability to concentrate urine.
4
Determine the required safety monitoring protocol for Clozapine.
Match Clozapine with absolute neutrophil count (ANC) monitoring.
Because Clozapine can cause potentially fatal agranulocytosis, strict hematologic monitoring is mandated.

Key Concept

Recognizing classic adverse effects, contraindications, and required monitoring for major psychotropic medications
Question 5Question →

A 45-year-old woman is brought to the emergency department by her husband due to a severe, throbbing headache, blurred vision, and chest palpitations that began 45 minutes ago. She has a 10-year history of major depressive disorder that was poorly responsive to multiple trials of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Six weeks ago, her psychiatrist started her on tranylcypromine. Vital signs are temperature 37.2°C (99.0°F), blood pressure 228/132 mm Hg, pulse 118/min, and respirations 20/min. Physical examination reveals profuse diaphoresis, facial flushing, and pupillary dilation. Neurological examination shows normal muscle tone, 2+ deep tendon reflexes symmetrically, and absent clonus. Mental status examination reveals an anxious woman who is fully oriented to person, place, and time. Her husband mentions they were celebrating their anniversary at a restaurant earlier this evening, where they shared a large platter of aged cheeses and cured meats. Which of the following is the most appropriate initial pharmacological intervention for this patient's current condition?

Show answer & explanation

Answer: Intravenous phentolamine

Answer

The most appropriate initial intervention is intravenous phentolamine.
The correct answer is intravenous phentolamine. This patient is presenting with a tyramine-induced hypertensive crisis, a classic and life-threatening complication of monoamine oxidase inhibitors (MAOIs) such as tranylcypromine. MAOIs irreversibly inhibit monoamine oxidase, the enzyme primarily responsible for breaking down dietary tyramine. When a patient on an MAOI consumes tyramine-rich foods (such as aged cheeses and cured meats), the tyramine enters the systemic circulation and acts as an indirect sympathomimetic. It displaces massive amounts of norepinephrine from presynaptic nerve terminals, leading to severe alpha-1 receptor-mediated vasoconstriction. This presents as a hypertensive emergency, often accompanied by severe headache, palpitations, diaphoresis, and flushing. The physical exam is crucial here: the absence of hyperreflexia, clonus, and lead-pipe rigidity distinguishes this condition from Serotonin Syndrome and Neuroleptic Malignant Syndrome. The most appropriate and life-saving initial treatment is a rapidly acting alpha-adrenergic antagonist, such as phentolamine, to counteract the profound vasoconstriction and lower the blood pressure.

Step-by-Step Solution

1
Analyze the patient's medication history and recent dietary intake.
The patient is taking tranylcypromine, a monoamine oxidase inhibitor (MAOI), and recently consumed aged cheeses and cured meats, which are rich in tyramine.
MAOIs inhibit the breakdown of tyramine in the gastrointestinal tract, leading to systemic tyramine absorption.
2
Evaluate the clinical presentation and physical examination findings.
The patient has extreme hypertension (228/132 mm Hg), sympathetic overactivity (diaphoresis, tachycardia, mydriasis), but normal neurological tone and reflexes without clonus.
These findings precisely match a tyramine-induced hypertensive crisis and rule out Serotonin Syndrome (which features hyperreflexia/clonus) and Neuroleptic Malignant Syndrome (which features severe rigidity).
3
Determine the pathophysiological mechanism of the crisis.
Systemic tyramine acts as an indirect sympathomimetic, displacing massive amounts of norepinephrine from presynaptic vesicles and causing severe alpha-1 mediated vasoconstriction.
Understanding the receptor profile involved dictates the pharmacological antidote.
4
Select the appropriate targeted pharmacological therapy.
Intravenous phentolamine (a short-acting, non-selective alpha-adrenergic antagonist) is selected to immediately reverse the severe alpha-mediated vasoconstriction.
Alpha-blockade is the definitive treatment; beta-blockers must be avoided to prevent unopposed alpha agonism.

Key Concept

Tyramine-induced hypertensive crisis in patients taking MAOIs is caused by massive norepinephrine release and is treated with alpha-adrenergic antagonists like phentolamine.
Estimated Time:1m 30s
Question 6Question →

Match each patient's clinical presentation of a psychotropic adverse effect with the medication most likely responsible.

Click a left item, then click its matching right item

Items

A 24-year-old woman develops a painful, blistering rash with oral mucosal ulcerations two weeks after initiating a new medication for bipolar depression.
A 42-year-old man exhibits sudden, sustained neck muscle contraction and upward eye deviation hours after receiving an intramuscular injection for severe agitation.
A 55-year-old man with bipolar I disorder presents with excessive thirst and frequent urination; laboratory tests show a low urine osmolality that remains unchanged after desmopressin administration.
A 35-year-old woman develops a resting tremor, slowed movements, and cogwheel rigidity several weeks after starting a medication for a recent psychotic episode.
A 29-year-old woman experiences severe dizziness, flu-like symptoms, and sensory disturbances described as 'brain zaps' 48 hours after abruptly discontinuing her daily medication for generalized anxiety disorder.

Matches

Show answer & explanation

Answer

Lamotrigine causes Stevens-Johnson syndrome; Haloperidol causes acute dystonia; Lithium causes nephrogenic diabetes insipidus; Risperidone causes drug-induced parkinsonism; Paroxetine causes antidepressant discontinuation syndrome.
Each patient presentation highlights a classic and severe side effect unique to or highly characteristic of a specific psychotropic medication. Recognizing these toxidromes is critical for safe medication management and rapid intervention.

Step-by-Step Solution

1
Identify the underlying diagnosis for the specific adverse effect described in each patient presentation.
The presentations describe Stevens-Johnson syndrome (rash with mucosal involvement), acute dystonia (torticollis/oculogyric crisis), nephrogenic diabetes insipidus (polyuria unresponsive to desmopressin), drug-induced parkinsonism (tremor/rigidity), and discontinuation syndrome (flu-like symptoms and 'brain zaps').
Accurately recognizing the toxidrome or side effect is the necessary first step to matching it with the offending medication.
2
Correlate each identified adverse effect with the psychotropic medication known to cause it based on its pharmacologic profile.
Stevens-Johnson syndrome is matched with Lamotrigine. Acute dystonia is matched with Haloperidol. Nephrogenic diabetes insipidus is matched with Lithium. Drug-induced parkinsonism is matched with Risperidone. Discontinuation syndrome is matched with Paroxetine.
Linking the clinical presentation to the offending agent demonstrates mastery of psychopharmacologic side effect profiles.

Key Concept

Psychotropic medication adverse effects and toxicity syndromes
Question 7Question →

A 35-year-old male construction worker is brought to the emergency department by his wife due to sudden-onset severe agitation, fever, and muscle stiffness. His medical history is significant for major depressive disorder, for which he has been taking sertraline for the past 2 years. Two days ago, the patient underwent a complex root canal procedure and was prescribed a short course of a centrally acting analgesic. On physical examination, his temperature is 39.4°C (102.9°F), blood pressure is 165/100 mmHg, and heart rate is 118/min. He is diaphoretic, flushed, and noticeably disoriented. Neurologic examination reveals bilateral ankle clonus, marked shivering, and generalized hyperreflexia that is most prominent in the lower extremities. Which of the following describes the mechanism of action of the analgesic that most likely precipitated this patient's current condition?

Show answer & explanation

Answer: Inhibition of presynaptic serotonin and norepinephrine reuptake

Answer

The correct answer is the inhibition of presynaptic serotonin and norepinephrine reuptake, representing the mechanism of tramadol.
The patient's clinical presentation of altered mental status, autonomic instability, and prominent neuromuscular hyperactivity (hyperreflexia, ankle clonus) in the setting of ongoing sertraline therapy is highly characteristic of serotonin syndrome. The precipitating event was the addition of a centrally acting analgesic. Tramadol is a unique analgesic because, in addition to acting as a weak mu-opioid receptor agonist, it inhibits the presynaptic reuptake of serotonin and norepinephrine. When combined with an SSRI like sertraline, tramadol can lead to excessive central serotonergic neurotransmission, precipitating life-threatening serotonin syndrome.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient exhibits autonomic instability (fever, hypertension, tachycardia, diaphoresis), altered mental status (agitation, disorientation), and neuromuscular hyperactivity (hyperreflexia, bilateral ankle clonus).
Identifying the toxidrome is the first step in determining the underlying etiology.
2
Correlate the toxidrome with the patient's medication history.
The clinical picture strongly indicates serotonin syndrome, especially given the patient's baseline use of an SSRI (sertraline).
Serotonin syndrome is a life-threatening condition caused by excessive serotonergic activity in the central nervous system.
3
Identify the precipitating medication.
The patient recently started a centrally acting analgesic for a dental procedure. Among analgesics, tramadol is known to trigger serotonin syndrome when combined with SSRIs.
Tramadol has unique serotonergic properties compared to traditional analgesics.
4
Recall the pharmacologic mechanism of the precipitant.
Tramadol acts as a weak mu-opioid receptor agonist and also inhibits the reuptake of serotonin and norepinephrine.
Answering the question requires matching the identified drug (tramadol) with its precise mechanism of action.

Key Concept

Serotonin syndrome can be precipitated by combining SSRIs with analgesics that have serotonergic activity, such as tramadol. Recognizing tramadol's dual mechanism of action (mu-opioid agonism and SNRI activity) is critical to avoiding this dangerous drug-drug interaction.
Question 8Question →

Match each patient's clinical scenario and specific medication requirement with the most appropriate second-generation antipsychotic.

Click a left item, then click its matching right item

Items

A 24-year-old man with schizophrenia is started on an antipsychotic that acts as a dopamine D2 partial agonist. Shortly after, he develops severe inner restlessness and an inability to sit still.
A 33-year-old woman with acute schizophrenia is prescribed an antipsychotic that must be taken with a 500-calorie meal for adequate absorption. A baseline electrocardiogram is ordered due to a known dose-dependent risk of QTc prolongation.
A 45-year-old man with schizoaffective disorder is prescribed a medication formulated specifically for sublingual administration to bypass extensive first-pass hepatic metabolism. He is told not to eat or drink for 10 minutes after dosing.
A 30-year-old woman with bipolar depression is prescribed an agent with potent 5-HT7 receptor antagonism. She is instructed to take the medication with a meal of at least 350 calories to ensure adequate clinical efficacy.

Matches

Show answer & explanation

Answer

The patient with akathisia and D2 partial agonism matches with Aripiprazole. The patient requiring a 500-calorie meal and an ECG for QTc prolongation matches with Ziprasidone. The patient requiring sublingual administration to bypass first-pass metabolism matches with Asenapine. The patient with bipolar depression requiring a 350-calorie meal matches with Lurasidone.
Each antipsychotic possesses distinct pharmacokinetic and pharmacodynamic properties that dictate its administration. Aripiprazole is a partial D2 agonist causing akathisia. Ziprasidone requires a 500-calorie meal and can prolong the QTc interval. Asenapine must be taken sublingually to avoid first-pass metabolism. Lurasidone requires a 350-calorie meal and acts at 5-HT7 receptors for treating bipolar depression.

Step-by-Step Solution

1
Identify the antipsychotic that acts as a D2 partial agonist and is strongly associated with akathisia.
Aripiprazole is the classic D2 partial agonist, which fundamentally alters its side effect profile, making akathisia highly prevalent while reducing hyperprolactinemia.
Recognizing aripiprazole's unique partial agonism is essential for differentiating its clinical effects from full antagonists.
2
Analyze the specific administration requirements and cardiac risks associated with the second vignette.
Ziprasidone requires a 500-calorie meal for optimal systemic absorption and carries a prominent warning for dose-dependent QTc prolongation.
Matching food requirements and specific toxicities (QTc prolongation) points directly to ziprasidone.
3
Determine the pharmacokinetic rationale for a sublingual atypical antipsychotic.
Asenapine is uniquely formulated for sublingual delivery because extensive first-pass hepatic metabolism renders the oral swallowed route ineffective.
This specific delivery mechanism and the instruction to avoid food/water for 10 minutes post-dose is pathognomonic for asenapine.
4
Evaluate the receptor profile and clinical indications of the remaining medication.
Lurasidone requires a 350-calorie meal, acts as a potent 5-HT7 antagonist, and is FDA-approved for bipolar depression without causing significant metabolic syndrome.
Synthesizing the exact caloric requirement with the bipolar depression indication confirms lurasidone.

Key Concept

Pharmacokinetic and pharmacodynamic profiles of second-generation antipsychotics
Question 9Question →

Match each patient's clinical presentation of an adverse drug reaction to the psychotropic medication most likely responsible for their symptoms.

Click a left item, then click its matching right item

Items

A patient develops a severe inner sense of restlessness and an uncontrollable urge to pace two weeks after initiating treatment for schizophrenia.
A patient treated for bipolar disorder presents with increased thirst, frequent urination, and a fine bilateral hand tremor.
A patient treated for major depressive disorder and insomnia presents to the emergency department with a painful, prolonged erection lasting over four hours.
A patient receiving treatment for refractory psychotic symptoms presents with a fever, severe pharyngitis, and an absolute neutrophil count of 300/mm³.
A patient recently started on a mood stabilizer for bipolar depression develops a rapidly spreading, painful blistering rash with oral mucosal ulcerations.

Matches

Show answer & explanation

Answer

The correct matches are: Restlessness (akathisia) with Haloperidol; Polyuria and tremor with Lithium; Priapism with Trazodone; Agranulocytosis with Clozapine; and Blistering rash with Lamotrigine.
Each psychotropic medication has a distinct and highly tested adverse effect profile. Recognizing these specific toxicities is crucial for appropriate monitoring and safe psychopharmacologic management.

Step-by-Step Solution

1
Analyze the first presentation (severe restlessness and pacing).
Identify this as akathisia, a common extrapyramidal symptom.
Haloperidol, a high-potency first-generation antipsychotic, has the highest risk of extrapyramidal symptoms among the choices provided.
2
Analyze the second presentation (polyuria, polydipsia, fine tremor).
Identify these as classic signs of lithium use.
Lithium commonly causes nephrogenic diabetes insipidus and neurologic side effects like fine tremors.
3
Analyze the third presentation (prolonged, painful erection).
Identify this as priapism.
Trazodone is well-known for causing priapism due to its alpha-1 adrenergic blockade.
4
Analyze the fourth presentation (fever, sore throat, severe neutropenia).
Identify this as agranulocytosis.
Clozapine carries a black box warning for agranulocytosis and requires continuous absolute neutrophil count monitoring.
5
Analyze the fifth presentation (blistering rash with mucosal involvement).
Identify this as Stevens-Johnson syndrome.
Lamotrigine is associated with a severe, potentially life-threatening rash, especially during rapid dose escalation.

Key Concept

Adverse effect profiles of psychotropic medications
Question 10Question →

A 24-year-old woman comes to the outpatient psychiatric clinic due to a 4-week history of feeling severely depressed, lacking energy, and sleeping 12 to 14 hours a day. She reports a loss of interest in her usual hobbies and a 5-kg (11-lb) weight gain over this period. The patient has no significant past medical history. Upon further questioning, the patient's roommate states that 8 months ago, the patient had a 10-day episode where she was extremely energetic, required only 3 hours of sleep per night, and spoke so rapidly it was difficult to interrupt her. During that time, she spontaneously booked an expensive, non-refundable trip to Europe that she could not afford. She was not hospitalized and eventually returned to her baseline. Which of the following is the most appropriate pharmacotherapy for this patient's current condition?

Show answer & explanation

Answer: Quetiapine

Answer

The correct answer is quetiapine, which is indicated for the treatment of acute bipolar depression.
The correct answer is quetiapine. This patient's current presentation of depressed mood, hypersomnia, weight gain, and anhedonia is consistent with a major depressive episode. However, her history of a distinct 10-day period of elevated energy, decreased need for sleep, pressured speech, and impulsive behavior indicates a past manic or hypomanic episode. Therefore, her underlying diagnosis is bipolar disorder, and she is currently experiencing acute bipolar depression. The most appropriate initial pharmacotherapy for acute bipolar depression includes certain second-generation antipsychotics (e.g., quetiapine, lurasidone) or mood stabilizers (e.g., lithium, lamotrigine). Quetiapine is FDA-approved as a monotherapy for this condition and is an excellent first-line choice.

Step-by-Step Solution

1
Identify the patient's current clinical syndrome.
The patient is experiencing a major depressive episode, characterized by depressed mood, hypersomnia, weight gain, fatigue, and anhedonia for 4 weeks.
Establishing the current phase of the mood disorder is necessary to guide symptom-specific treatment.
2
Evaluate the patient's psychiatric history for prior mood episodes.
The patient had a previous 10-day episode of decreased need for sleep, rapid speech, increased energy, and impulsivity (booking an expensive trip).
A history of mania or hypomania fundamentally changes the diagnosis from major depressive disorder to bipolar disorder.
3
Determine the appropriate pharmacotherapy for acute bipolar depression.
Select an agent with proven efficacy for bipolar depression that does not risk inducing a manic switch, such as quetiapine.
Antidepressant monotherapy is contraindicated in bipolar disorder due to the risk of mood destabilization and manic switch.

Key Concept

Management of acute bipolar depression and avoidance of antidepressant monotherapy
Question 11Question →

A collegiate gymnast presents to the student health center for evaluation of a persistently depressed mood, profound fatigue, and anhedonia over the past three months. During the interview, she expresses deep dissatisfaction with her body shape and an intense fear of gaining weight. Vital signs show a heart rate of 54 /min54 \text{ /min} and a blood pressure of 92/58 mm Hg92/58 \text{ mm Hg}. Physical examination reveals a body mass index of 17.4 kg/m217.4 \text{ kg/m}^2, fine downy hair on her arms, and bilateral parotid gland enlargement. Laboratory results are notable for a serum potassium of 3.2 mEq/L3.2 \text{ mEq/L}. She asks the physician to prescribe an antidepressant she read about online, describing it as 'the one that does not cause weight gain or sexual problems.' If the physician complies and prescribes this specific medication, the patient would be at significantly increased risk for which of the following complications?

Show answer & explanation

Answer: Generalized seizures

Answer

Generalized seizures
The correct answer is generalized seizures. The patient's clinical presentation—including a low body mass index, bradycardia, lanugo (fine downy hair), parotid gland enlargement, and hypokalemia—is highly indicative of an eating disorder with purging behavior. She is requesting an antidepressant that is weight-neutral and lacks sexual side effects, which accurately describes bupropion. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that is known to lower the seizure threshold in a dose-dependent manner. It is absolutely contraindicated in patients with anorexia nervosa or bulimia nervosa. These conditions frequently cause severe electrolyte abnormalities (such as this patient's hypokalemia) that independently lower the seizure threshold, placing the patient at an extreme risk for developing generalized tonic-clonic seizures if bupropion is administered.

Step-by-Step Solution

1
Identify the patient's underlying psychiatric and medical condition based on the clinical presentation.
The patient has major depressive disorder comorbid with an eating disorder (anorexia nervosa, binge-eating/purging type), indicated by her low BMI, intense fear of weight gain, bradycardia, lanugo, parotid enlargement, and hypokalemia.
Recognizing the comorbid eating disorder and its physiologic consequences (electrolyte abnormalities) is crucial for safe psychopharmacologic selection.
2
Identify the specific medication the patient is requesting based on her description.
The medication requested is bupropion, a norepinephrine-dopamine reuptake inhibitor (NDRI).
Bupropion is uniquely known among antidepressants for being weight-neutral (or causing weight loss) and having an absence of sexual side effects.
3
Determine the primary adverse risk and contraindication of the requested medication in this specific patient population.
Bupropion causes a dose-dependent lowering of the seizure threshold and is therefore strictly contraindicated in patients with anorexia nervosa or bulimia nervosa.
Patients with eating disorders frequently suffer from electrolyte derangements (like this patient's hypokalemia) that independently lower the seizure threshold, making the administration of bupropion highly epileptogenic.

Key Concept

Bupropion is an activating antidepressant that lacks sexual side effects and does not cause weight gain, but it is strictly contraindicated in patients with eating disorders (anorexia and bulimia nervosa) due to an unacceptably high risk of generalized seizures.
Question 12Question →

A medical student on a psychiatry clerkship is reviewing the adverse effect profiles of commonly prescribed psychiatric medications. Match each of the following psychotropic medications to the clinical vignette that best describes its characteristic adverse effect or toxicity.

Click a left item, then click its matching right item

Items

Clozapine
Lamotrigine
Lithium
Bupropion
Ziprasidone

Matches

Show answer & explanation

Answer

Clozapine matches with agranulocytosis; Lamotrigine matches with Stevens-Johnson syndrome; Lithium matches with toxicity exacerbated by thiazides; Bupropion matches with seizures in eating disorders; Ziprasidone matches with QTc prolongation.
Each psychotropic medication has a unique, high-yield adverse effect profile that must be recognized to ensure patient safety. Clozapine requires strict ANC monitoring due to agranulocytosis risk. Lamotrigine must be titrated slowly to prevent Stevens-Johnson syndrome. Lithium has a narrow therapeutic window, and toxicity is easily precipitated by volume depletion or thiazides. Bupropion lowers the seizure threshold and is contraindicated in eating disorders. Ziprasidone is strongly associated with QTc prolongation.

Step-by-Step Solution

1
Analyze the side effect profile for Clozapine.
Identify that Clozapine can cause life-threatening agranulocytosis, presenting with fever, sore throat, and low ANC.
This is a mandatory safety parameter monitored via the REMS program.
2
Analyze the side effect profile for Lamotrigine.
Identify that Lamotrigine can cause Stevens-Johnson syndrome, a severe blistering mucosal rash, especially with fast titration.
Understanding titration protocols is essential to prevent this dermatologic emergency.
3
Analyze the side effect profile for Lithium.
Identify that Lithium causes nephrogenic diabetes insipidus and has a narrow therapeutic index; toxicity (ataxia, tremor) is worsened by thiazide diuretics.
Drug-drug interactions are critical in managing patients on mood stabilizers.
4
Analyze the side effect profile for Bupropion.
Identify that Bupropion lowers the seizure threshold, making it contraindicated in bulimia nervosa due to electrolyte imbalances.
Matching contraindications with patient history ensures safe prescribing.
5
Analyze the side effect profile for Ziprasidone.
Identify that Ziprasidone is associated with significant QTc prolongation.
ECG monitoring may be required to prevent arrhythmias like torsades de pointes.

Key Concept

Psychotropic Medication Adverse Effects
Question 13Question →

A 54-year-old woman is brought to the emergency department by her daughter due to progressive confusion, unsteadiness, and shaking. The patient has a history of bipolar I disorder that has been well controlled on a stable dose of lithium for the past 8 years. Two weeks ago, she visited a primary care clinic for routine evaluation and was started on a new daily medication. Today, her temperature is 37.1°C (98.8°F), blood pressure is 128/78 mm Hg, and heart rate is 82/min. Physical examination reveals an unsteady, broad-based gait and a coarse tremor in both hands. Deep tendon reflexes are 3+ bilaterally. She also reports several days of nausea, vomiting, and diarrhea. Which of the following medications was most likely added to her regimen two weeks ago?

Show answer & explanation

Answer: Hydrochlorothiazide

Answer

Hydrochlorothiazide
The patient's presentation of confusion, ataxia, a coarse tremor, hyperreflexia, and gastrointestinal distress (nausea, vomiting, diarrhea) in the setting of chronic lithium therapy is highly characteristic of acute-on-chronic lithium toxicity. Lithium has a very narrow therapeutic index and is eliminated almost entirely by the kidneys. Thiazide diuretics (e.g., hydrochlorothiazide) inhibit the Na+/Cl- cotransporter in the distal convoluted tubule. This leads to mild volume depletion, which stimulates the kidneys to compensatorily increase sodium reabsorption in the proximal tubule. Because lithium is handled similarly to sodium in the proximal tubule, its reabsorption is concurrently increased, severely decreasing its clearance and precipitating toxicity. Other common drugs that increase lithium levels include NSAIDs, ACE inhibitors, and tetracyclines.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and medication history.
The patient is on chronic lithium therapy and presents with acute neurologic (confusion, ataxia, coarse tremor, hyperreflexia) and gastrointestinal (nausea, vomiting, diarrhea) symptoms.
Identifying the clinical syndrome is necessary to determine the underlying pathophysiology.
2
Synthesize the findings to establish a diagnosis.
The combination of these specific neurologic and GI findings in a patient taking lithium is the classic presentation of acute-on-chronic lithium toxicity.
Lithium has a narrow therapeutic index and specific toxidrome characteristics.
3
Identify potential triggers for the toxicity based on the timeline.
A new medication was added two weeks ago. Medications that classically decrease lithium clearance include thiazide diuretics, NSAIDs, ACE inhibitors, and tetracyclines.
Lithium is almost exclusively excreted by the kidneys, and drugs affecting renal sodium handling alter its clearance.
4
Select the correct medication from the given options.
Hydrochlorothiazide is a thiazide diuretic that causes volume depletion, leading to increased proximal tubule reabsorption of both sodium and lithium, thereby precipitating toxicity.
This directly explains the patient's presentation following the addition of the new drug.

Key Concept

Lithium Toxicity and Drug Interactions
Question 14Question →

You are evaluating five different patients who have recently initiated psychotropic medications. Each patient is now presenting with a specific adverse effect based on their history and examination findings. Which primary pharmacological mechanism best corresponds to the responsible medication for each patient's clinical presentation?

Click a left item, then click its matching right item

Items

A 32-year-old woman with bulimia nervosa and normal vital signs presents with postictal confusion following a generalized tonic-clonic seizure shortly after starting a new antidepressant.
A 45-year-old man with depression and severe insomnia presents in acute distress with a painful, sustained penile erection lasting 6 hours after taking a newly prescribed sleep aid.
A 29-year-old woman with treatment-resistant depression presents with diaphoresis, severe anxiety on mental status exam, and a blood pressure of 220/115 mm Hg after attending a wine and aged cheese tasting.
A 55-year-old man with major depressive disorder and diabetic neuropathy presents with a euthymic mood but new-onset resting hypertension (155/95 mm Hg) following a dose increase of his medication.
A 24-year-old man treated for depression presents with significant recent weight gain (5 kg) and complains of profound daytime sedation and dizziness upon standing (orthostatic hypotension).

Matches

Show answer & explanation

Answer

Match each clinical presentation to the underlying mechanism of action of the responsible psychotropic medication: 1-Bupropion, 2-Trazodone, 3-MAOI, 4-SNRI, 5-Mirtazapine.
Bupropion causes seizures in patients with eating disorders due to NE/DA reuptake inhibition. Trazodone causes priapism via alpha-1 antagonism. MAOIs cause tyramine hypertensive crisis by inhibiting monoamine oxidase. SNRIs like venlafaxine cause dose-dependent hypertension via NE reuptake inhibition. Mirtazapine causes sedation, weight gain, and orthostasis via H1 and alpha-1/alpha-2 antagonism.

Step-by-Step Solution

1
Analyze each clinical vignette to identify the specific psychotropic medication based on the unique adverse effect profile and the patient's history.
Identified medications: Bupropion (Left 1), Trazodone (Left 2), MAOI (Left 3), Venlafaxine/SNRI (Left 4), Mirtazapine (Left 5).
Recognizing the classic clinical presentation of drug-specific side effects is required before determining the mechanism of action.
2
Determine the pharmacological mechanism of action for each identified medication.
Bupropion inhibits NE/DA reuptake. Trazodone inhibits serotonin reuptake and blocks alpha-1 receptors. MAOIs irreversibly inhibit monoamine oxidase. Venlafaxine inhibits serotonin and dose-dependently inhibits NE reuptake. Mirtazapine blocks alpha-2 and H1 receptors.
Understanding the receptor-level activity explains why these specific adverse effects occur in these clinical scenarios.
3
Map the identified mechanism of action to the corresponding right item for each patient scenario.
All 5 pairs are successfully matched according to their pharmacological profiles.
This completes the matching process by synthesizing clinical diagnostics with neuropharmacology.

Key Concept

The mechanisms of action of psychotropic medications directly correlate with their unique and potentially dangerous adverse effect profiles.
Question 15Question →

A 35-year-old man with a history of schizophrenia is brought to the emergency department from a residential psychiatric facility due to high fever, severe muscle rigidity, and progressive confusion over the past 24 hours. His current medication regimen includes high-dose fluphenazine. His temperature is 39.8°C (103.6°F), blood pressure is 168/104 mm Hg, and pulse is 122/min. Physical examination reveals generalized lead-pipe rigidity and profuse diaphoresis. Laboratory studies show a markedly elevated creatine kinase level. Arrange the following interventions in the most appropriate sequential order for the standard step-wise management of this patient's condition, from the initial immediate action to the last-resort treatment.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequential order for managing Neuroleptic Malignant Syndrome (NMS) is: 1) Discontinue the offending antipsychotic medication, 2) Initiate intensive supportive care with intravenous fluids and cooling measures, 3) Administer targeted pharmacotherapy such as bromocriptine or dantrolene, and 4) Consider electroconvulsive therapy (ECT).
The management of neuroleptic malignant syndrome (NMS) follows a specific, step-wise protocol based on clinical severity and response. The absolute first and most essential step is to discontinue the offending dopamine antagonist. Immediately following this, the mainstay of early management is aggressive supportive care, which includes substantial intravenous hydration to flush myoglobin and prevent acute kidney injury, alongside cooling blankets to manage hyperthermia. If the patient does not demonstrate adequate clinical improvement with these initial conservative measures, the next step is to initiate specific pharmacotherapy, such as bromocriptine (a dopamine agonist to overcome the blockade) or dantrolene (a ryanodine receptor antagonist to relax skeletal muscle). Finally, in severe, life-threatening cases that remain refractory to all medical interventions, electroconvulsive therapy (ECT) is considered as the definitive treatment.

Step-by-Step Solution

1
Identify the primary clinical diagnosis based on the vignette.
The patient has Neuroleptic Malignant Syndrome (NMS).
The presentation of high fever, lead-pipe rigidity, autonomic instability, altered mental status, and elevated creatine kinase in a patient taking fluphenazine (a typical antipsychotic) is classic for NMS.
2
Determine the most urgent initial intervention.
Discontinue fluphenazine.
Removing the causative agent is the mandatory first step to halt the progression of the syndrome.
3
Determine the next immediate line of treatment.
Initiate supportive care.
Aggressive intravenous hydration and cooling measures are required immediately to prevent complications such as acute kidney injury and cardiovascular collapse.
4
Identify the step for refractory symptoms.
Administer bromocriptine or dantrolene.
Specific pharmacotherapy is utilized when cessation of the drug and supportive measures are insufficient.
5
Identify the last-line treatment option.
Consider ECT.
ECT is highly effective for NMS but is reserved for severe, treatment-resistant cases.

Key Concept

The step-wise management of Neuroleptic Malignant Syndrome prioritizes stopping the offending agent, followed by supportive care, targeted medications, and finally ECT.
Question 16Question →

A 34-year-old man with a history of treatment-resistant depression is brought to the emergency department by his partner. The patient was doing well on a newly prescribed psychiatric medication until this morning, when he took an over-the-counter nasal decongestant for a severe cold. Within an hour of taking the cold medication, he developed a severe, throbbing headache, blurred vision, and neck stiffness. On triage, his temperature is 37.1°C (98.8°F), pulse is 115/min, and blood pressure is 220/125 mm Hg. Physical examination shows diaphoresis and normal deep tendon reflexes without clonus. Which of the following psychiatric medications is this patient most likely taking?

Show answer & explanation

Answer: Phenelzine

Answer

Phenelzine
The correct psychiatric medication is an MAOI, such as phenelzine. Monoamine oxidase inhibitors (MAOIs) work by irreversibly inhibiting the enzyme monoamine oxidase, thereby preventing the breakdown of monoamines including serotonin, norepinephrine, and dopamine. When a patient taking an MAOI consumes a sympathomimetic drug, such as pseudoephedrine or phenylephrine found in over-the-counter nasal decongestants, it triggers a massive release or accumulation of catecholamines. This classically precipitates a sudden and potentially life-threatening hypertensive crisis, presenting with markedly elevated blood pressure, severe throbbing headache, diaphoresis, and neck stiffness. The absence of hyperreflexia and clonus helps rule out serotonin syndrome.

Step-by-Step Solution

1
Identify the patient's acute clinical syndrome based on the physical examination and vitals.
The patient is experiencing a sudden, severe hypertensive crisis (blood pressure 220/125 mm Hg) accompanied by a throbbing headache and diaphoresis, without clonus or hyperreflexia.
Establishing the specific toxidrome narrows down the possible pathophysiologic mechanisms.
2
Determine the inciting trigger for the hypertensive crisis.
The symptoms began immediately after taking an over-the-counter nasal decongestant, which contains sympathomimetics like pseudoephedrine or phenylephrine.
Identifying the precipitating agent is necessary to recognize the specific drug-drug interaction.
3
Match the drug interaction with the appropriate class of psychiatric medications.
Monoamine oxidase inhibitors (MAOIs) interact dangerously with sympathomimetics, leading to excessive catecholamines and resulting in a hypertensive crisis.
This confirms which psychiatric drug class causes this classic presentation.

Key Concept

Drug-drug interactions involving Monoamine Oxidase Inhibitors (MAOIs) and sympathomimetics leading to hypertensive crisis.
Estimated Time:1m 0s
Question 17Question →

A 42-year-old woman is brought to the emergency department by her husband due to worsening confusion, severe nausea, vomiting, and a prominent hand tremor. Her husband reports that she has been unusually unsteady on her feet for the past three days. Her medical history is significant for bipolar disorder, which has been well-controlled on a stable dose of lithium for the past five years. Three weeks ago, she was diagnosed with essential hypertension by her primary care provider and was started on a new daily medication. On physical examination, the patient is lethargic and exhibits a coarse resting tremor, hyperreflexia, and ataxia. Her serum lithium level is 2.1 mEq/L (therapeutic range: 0.6-1.2 mEq/L). Which of the following antihypertensive medications was most likely prescribed to this patient?

Show answer & explanation

Answer: Hydrochlorothiazide

Answer

Hydrochlorothiazide
The correct answer is hydrochlorothiazide. This patient is experiencing acute lithium toxicity, characterized by gastrointestinal symptoms, coarse tremor, ataxia, and confusion, confirmed by an elevated serum lithium level. Lithium is almost entirely excreted by the kidneys. Thiazide diuretics (such as hydrochlorothiazide) inhibit sodium reabsorption in the distal convoluted tubule, leading to mild hypovolemia. This volume depletion stimulates the kidneys to increase sodium reabsorption in the proximal convoluted tubule. Because lithium is handled similarly to sodium by the kidneys, lithium reabsorption is concurrently increased in the proximal tubule. This leads to decreased lithium clearance and a rapid accumulation of the drug to toxic levels. Other common medications that precipitate lithium toxicity include NSAIDs, ACE inhibitors, and ARBs.

Step-by-Step Solution

1
Identify the patient's acute clinical presentation.
The patient presents with confusion, ataxia, coarse tremor, and gastrointestinal distress, confirmed by an elevated serum lithium level of 2.1 mEq/L.
Recognizing the clinical syndrome of lithium toxicity is the essential first step in determining its underlying cause.
2
Correlate the toxicity with recent changes in medical management.
The toxicity began shortly after starting a new antihypertensive medication three weeks ago.
Lithium has a narrow therapeutic index, and its serum levels are highly sensitive to concurrent medications that alter renal function.
3
Determine which class of antihypertensives decreases lithium clearance.
Thiazide diuretics (like hydrochlorothiazide) are classic agents that decrease renal lithium clearance and precipitate toxicity.
Thiazides cause mild volume depletion, triggering a compensatory increase in proximal tubular reabsorption of sodium and lithium.

Key Concept

Lithium has a narrow therapeutic index and is almost exclusively cleared by the kidneys. Its renal clearance is significantly decreased by concurrent use of thiazide diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and angiotensin-converting enzyme (ACE) inhibitors, which can rapidly lead to potentially fatal toxicity.
Question 18Question →

A 2828-year-old woman with a history of severe bipolar I disorder presents to the clinic for an initial prenatal visit at 66 weeks gestation. She is currently stable on lithium carbonate and has not experienced a manic episode in 33 years. However, she has a history of life-threatening manic episodes with psychotic features whenever she has attempted to discontinue her medication in the past. She wishes to continue her pregnancy. Arrange the following steps in the optimal pharmacological and obstetric management of this patient in chronological order, from the first trimester through the immediate postpartum period.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing a pregnant patient on lithium with severe bipolar disorder is: First, continue lithium and counsel on teratogenic risks at the initial visit; second, perform a fetal echocardiogram at 1818 to 2222 weeks; third, increase monitoring frequency to weekly in the third trimester; fourth, withhold lithium at the onset of active labor; and finally, resume the pre-pregnancy dose immediately postpartum.
The optimal management of a pregnant patient with severe bipolar I disorder on lithium involves a delicate chronological balance of teratogenic risk assessment and physiological changes. At 66 weeks gestation, the first step is to counsel the patient about the absolute risk of Ebstein anomaly and continue the medication, as abrupt discontinuation carries a catastrophic risk of relapse. During the second trimester (1818 to 2222 weeks), a targeted fetal echocardiogram must be ordered to screen for structural cardiac defects resulting from first-trimester exposure. As the pregnancy progresses into the third trimester, the maternal glomerular filtration rate (GFR) and plasma volume reach peak levels, increasing lithium clearance; therefore, monitoring frequency must be increased to weekly, and the dose is often adjusted upward. At the onset of active labor, massive fluid shifts and potential dehydration can rapidly decrease lithium clearance and precipitate acute toxicity, requiring the medication to be temporarily withheld. Finally, immediately following delivery, maternal GFR normalizes rapidly. The patient must be quickly returned to her pre-pregnancy lithium dose to avoid toxicity from the higher third-trimester dose while providing critical prophylaxis against the extremely high risk of postpartum mania.

Step-by-Step Solution

1
Determine first trimester management for severe bipolar disorder.
Counsel on the risk of Ebstein anomaly and continue the medication (item_1).
The absolute risk of Ebstein anomaly is relatively low (roughly 11 in 1,0001,000 to 11 in 2,0002,000), whereas a manic relapse off medication poses a severe threat to both mother and fetus.
2
Identify the appropriate obstetric screening for lithium exposure.
Schedule a targeted fetal echocardiogram (item_2).
Fetal cardiac development and structural anomalies caused by early lithium exposure can be optimally assessed between 1818 and 2222 weeks gestation.
3
Adjust management for late-pregnancy physiological changes.
Increase lithium monitoring to weekly in the third trimester (item_3).
Peak increases in maternal blood volume and glomerular filtration rate occur in the third trimester, leading to increased renal clearance of lithium and potential subtherapeutic levels.
4
Determine appropriate management during delivery.
Withhold lithium during active labor (item_4).
Massive fluid shifts, blood loss, and dehydration during labor can rapidly concentrate serum lithium, risking acute maternal toxicity.
5
Determine immediate postpartum management.
Resume the pre-pregnancy dose immediately after delivery (item_5).
Maternal GFR rapidly normalizes postpartum. Returning to the pre-pregnancy dose prevents toxicity while protecting against the very high risk of postpartum mania in bipolar I disorder.

Key Concept

The management of lithium therapy in pregnancy involves continuing the drug in severe bipolar disorder, screening for Ebstein anomaly via second-trimester fetal echocardiography, adjusting for third-trimester GFR increases, withholding during labor to prevent toxicity, and immediately resuming pre-pregnancy doses postpartum.
Estimated Time:1m 30s
Question 19Question →

A 52-year-old man is brought to the emergency department by his wife due to worsening confusion, unsteadiness, and a prominent tremor over the past three days. He has a history of bipolar I disorder that has been well controlled on lithium carbonate for the past five years. Two weeks ago, he was diagnosed with essential hypertension, and a new daily medication was added to his regimen. His temperature is 37.1 C (98.8 F), blood pressure is 135/85 mm Hg, and pulse is 88/min. On examination, the patient is lethargic but arousable. Neurological examination reveals dysarthria, an unsteady, broad-based gait, and a coarse resting tremor in both hands. Laboratory studies show a serum creatinine of 1.2 mg/dL (baseline 0.9 mg/dL) and a serum lithium level of 2.1 mEq/L (therapeutic range: 0.6-1.2 mEq/L). Which of the following best describes the mechanism by which the new antihypertensive medication precipitated this patient's condition?

Show answer & explanation

Answer: Decreased renal clearance due to volume depletion and increased proximal tubule reabsorption

Answer

Decreased renal clearance due to volume depletion and increased proximal tubule reabsorption
The patient presents with acute lithium toxicity, characterized by neurologic symptoms (confusion, ataxia, dysarthria, and a coarse tremor) and an elevated serum lithium level. The most likely precipitant is the recent addition of a thiazide diuretic (e.g., hydrochlorothiazide) for essential hypertension. Thiazide diuretics act at the distal convoluted tubule to increase sodium and water excretion, leading to mild systemic volume depletion. This hypovolemia triggers the renin-angiotensin-aldosterone system and a compensatory increase in sodium reabsorption at the proximal convoluted tubule (PCT). Because lithium and sodium share similar transport mechanisms in the kidney, lithium reabsorption is concomitantly increased at the PCT. This results in decreased renal clearance of lithium, rapid accumulation, and subsequent toxicity. Other common drugs that decrease lithium clearance include NSAIDs (via decreased afferent arteriolar blood flow) and ACE inhibitors/ARBs.

Step-by-Step Solution

1
Evaluate the clinical presentation and laboratory results.
The patient exhibits confusion, ataxia, dysarthria, a coarse tremor, and a supratherapeutic serum lithium level (2.1 mEq/L), consistent with acute lithium toxicity.
Recognizing the toxic syndrome is the necessary first step to determine its underlying etiology.
2
Identify the precipitating event.
The recent initiation of a new antihypertensive medication is the likely trigger for the toxicity.
Several common drug classes interact dangerously with lithium, most notably certain antihypertensives and analgesics.
3
Determine the pharmacokinetic interaction between the likely antihypertensive (a thiazide diuretic) and lithium.
Thiazides induce volume depletion, which triggers a compensatory increase in the reabsorption of sodium and lithium in the proximal convoluted tubule, decreasing overall renal clearance.
Lithium shares renal transport mechanisms with sodium, making its clearance highly dependent on the patient's volume status and concurrent diuretic use.

Key Concept

Pharmacokinetic interactions of Lithium
Question 20Question →

A 42-year-old woman is brought to the emergency department by her husband due to a 2-day history of worsening confusion, slurred speech, and an unsteady gait. She also reports several episodes of severe nausea and vomiting. Her medical history is significant for bipolar I disorder, which has been well-controlled on a stable dose of lithium carbonate for the past 4 years. Two weeks ago, she was evaluated by her primary care physician for newly diagnosed essential hypertension, and a daily medication was added to her regimen. Her temperature is 37.1°C (98.8°F), blood pressure is 128/82 mmHg, and pulse is 84/min. On physical examination, the patient appears lethargic. Neurological examination reveals a coarse, irregular resting tremor in both hands and truncal ataxia. Which of the following medications was most likely recently prescribed to this patient?

Show answer & explanation

Answer: Hydrochlorothiazide

Answer

Hydrochlorothiazide
The patient is presenting with classic signs of severe lithium toxicity, which include altered mental status, coarse tremors, ataxia, and gastrointestinal distress. Lithium has a narrow therapeutic index and is primarily cleared by the kidneys, where it is handled similarly to sodium. Thiazide diuretics, such as hydrochlorothiazide, inhibit the Na+/Cl- cotransporter in the distal convoluted tubule. The resulting mild volume depletion triggers a compensatory increase in the reabsorption of both sodium and lithium in the proximal convoluted tubule. This significantly decreases lithium clearance and rapidly leads to toxicity. Other common medications that increase lithium levels include NSAIDs (except aspirin), ACE inhibitors, and ARBs.

Step-by-Step Solution

1
Identify the patient's acute clinical syndrome based on the presentation.
The patient has acute-on-chronic lithium toxicity, characterized by gastrointestinal symptoms (nausea, vomiting) and severe neurologic signs (lethargy, confusion, ataxia, slurred speech, coarse tremors).
Recognizing the toxicity syndrome is required to determine which recent medication change precipitated the adverse event.
2
Determine the pharmacokinetic relationship between the new hypertension diagnosis and lithium clearance.
Lithium has a narrow therapeutic index and is cleared almost entirely by the kidneys. Its reabsorption in the proximal convoluted tubule is closely coupled with sodium.
Understanding lithium's renal handling allows the identification of drug classes that alter its excretion.
3
Select the antihypertensive medication that most significantly impairs lithium clearance.
Hydrochlorothiazide causes volume depletion, which triggers a compensatory increase in the reabsorption of both sodium and lithium in the proximal tubule, leading to systemic toxicity.
Thiazide diuretics are a classic and highly tested cause of drug-induced lithium toxicity.

Key Concept

Lithium toxicity can be precipitated by medications that decrease its renal clearance, most notably thiazide diuretics, NSAIDs, ACE inhibitors, and angiotensin II receptor blockers (ARBs).
Page 1 / 4Next
Psychopharmacology and Psychological Therapies Practice Questions — USMLE Step 2 CK | Examkin